Global Zika Virus Testing Industry

New York, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Zika Virus Testing Industry" - https://www.reportlinker.com/p05960560/?utm_source=GNW
6 Million by 2027, growing at aCAGR of 6.4% over the period 2020-2027. Nucleic Acid Amplification Testing (NAAT), one of the segments analyzed in the report, is projected to record 6.8% CAGR and reach US$129.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Serological Testing segment is readjusted to a revised 6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $43.1 Million, While China is Forecast to Grow at 9.8% CAGR

The Zika Virus Testing market in the U.S. is estimated at US$43.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$53.1 Million by the year 2027 trailing a CAGR of 9.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.5% and 5.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.We bring years of research experience to this 6th edition of our report. The 185-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

• Biocan Diagnostics
• Chembio Diagnostic Systems, Inc.
• F. Hoffmann-La Roche AG
• Hologic, Inc.
• Quest Diagnostics, Inc.
• SD Biosensor, Inc.

Read the full report: https://www.reportlinker.com/p05960560/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Zika Virus Testing Competitor Market Share Scenario Worldwide
(in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Zika Virus Testing
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027

Table 2: World Historic Review for Zika Virus Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019

Table 3: World 15-Year Perspective for Zika Virus Testing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Nucleic Acid
Amplification Testing (NAAT) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ for Years 2020 through 2027

Table 5: World Historic Review for Nucleic Acid Amplification
Testing (NAAT) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019

Table 6: World 15-Year Perspective for Nucleic Acid
Amplification Testing (NAAT) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Serological
Testing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ for Years
2020 through 2027

Table 8: World Historic Review for Serological Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019

Table 9: World 15-Year Perspective for Serological Testing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Zika Virus Testing Market Share (in %) by Company: 2019 & 2025
Market Analytics
Table 10: USA Current & Future Analysis for Zika Virus Testing
by Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027

Table 11: USA Historic Review for Zika Virus Testing by Segment -
Nucleic Acid Amplification Testing (NAAT) and Serological
Testing Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019

Table 12: USA 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

CANADA
Table 13: Canada Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 14: Canada Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 15: Canada 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

JAPAN
Table 16: Japan Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 17: Japan Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 18: Japan 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

CHINA
Table 19: China Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 20: China Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 21: China 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

EUROPE
Market Facts & Figures
European Zika Virus Testing Market: Competitor Market Share
Scenario (in %) for 2019 & 2025
Market Analytics
Table 22: Europe Current & Future Analysis for Zika Virus
Testing by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027

Table 23: Europe Historic Review for Zika Virus Testing by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 24: Europe 15-Year Perspective for Zika Virus Testing by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 25: Europe Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 26: Europe Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 27: Europe 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

FRANCE
Table 28: France Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 29: France Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 30: France 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

GERMANY
Table 31: Germany Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 32: Germany Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 33: Germany 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

ITALY
Table 34: Italy Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 35: Italy Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 36: Italy 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

UNITED KINGDOM
Table 37: UK Current & Future Analysis for Zika Virus Testing
by Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027

Table 38: UK Historic Review for Zika Virus Testing by Segment -
Nucleic Acid Amplification Testing (NAAT) and Serological
Testing Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019

Table 39: UK 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

SPAIN
Table 40: Spain Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 41: Spain Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 42: Spain 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

RUSSIA
Table 43: Russia Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 44: Russia Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 45: Russia 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

REST OF EUROPE
Table 46: Rest of Europe Current & Future Analysis for Zika
Virus Testing by Segment - Nucleic Acid Amplification Testing
(NAAT) and Serological Testing - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027

Table 47: Rest of Europe Historic Review for Zika Virus Testing
by Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 48: Rest of Europe 15-Year Perspective for Zika Virus
Testing by Segment - Percentage Breakdown of Value Sales for
Nucleic Acid Amplification Testing (NAAT) and Serological
Testing for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 49: Asia-Pacific Current & Future Analysis for Zika Virus
Testing by Geographic Region - Australia, India, South Korea
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Sales in US$ for Years 2020 through 2027

Table 50: Asia-Pacific Historic Review for Zika Virus Testing
by Geographic Region - Australia, India, South Korea and Rest
of Asia-Pacific Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019

Table 51: Asia-Pacific 15-Year Perspective for Zika Virus
Testing by Geographic Region - Percentage Breakdown of Value
Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027

Table 52: Asia-Pacific Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 53: Asia-Pacific Historic Review for Zika Virus Testing
by Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 54: Asia-Pacific 15-Year Perspective for Zika Virus
Testing by Segment - Percentage Breakdown of Value Sales for
Nucleic Acid Amplification Testing (NAAT) and Serological
Testing for the Years 2012, 2020 & 2027

AUSTRALIA
Table 55: Australia Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 56: Australia Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 57: Australia 15-Year Perspective for Zika Virus Testing
by Segment - Percentage Breakdown of Value Sales for Nucleic
Acid Amplification Testing (NAAT) and Serological Testing for
the Years 2012, 2020 & 2027

INDIA
Table 58: India Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 59: India Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 60: India 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

SOUTH KOREA
Table 61: South Korea Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 62: South Korea Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 63: South Korea 15-Year Perspective for Zika Virus
Testing by Segment - Percentage Breakdown of Value Sales for
Nucleic Acid Amplification Testing (NAAT) and Serological
Testing for the Years 2012, 2020 & 2027

REST OF ASIA-PACIFIC
Table 64: Rest of Asia-Pacific Current & Future Analysis for
Zika Virus Testing by Segment - Nucleic Acid Amplification
Testing (NAAT) and Serological Testing - Independent Analysis
of Annual Sales in US$ for the Years 2020 through 2027

Table 65: Rest of Asia-Pacific Historic Review for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019

Table 66: Rest of Asia-Pacific 15-Year Perspective for Zika
Virus Testing by Segment - Percentage Breakdown of Value Sales
for Nucleic Acid Amplification Testing (NAAT) and Serological
Testing for the Years 2012, 2020 & 2027

LATIN AMERICA
Table 67: Latin America Current & Future Analysis for Zika
Virus Testing by Geographic Region - Argentina, Brazil, Mexico
and Rest of Latin America Markets - Independent Analysis of
Annual Sales in US$ for Years 2020 through 2027

Table 68: Latin America Historic Review for Zika Virus Testing
by Geographic Region - Argentina, Brazil, Mexico and Rest of
Latin America Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019

Table 69: Latin America 15-Year Perspective for Zika Virus
Testing by Geographic Region - Percentage Breakdown of Value
Sales for Argentina, Brazil, Mexico and Rest of Latin America
Markets for Years 2012, 2020 & 2027

Table 70: Latin America Current & Future Analysis for Zika
Virus Testing by Segment - Nucleic Acid Amplification Testing
(NAAT) and Serological Testing - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027

Table 71: Latin America Historic Review for Zika Virus Testing
by Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 72: Latin America 15-Year Perspective for Zika Virus
Testing by Segment - Percentage Breakdown of Value Sales for
Nucleic Acid Amplification Testing (NAAT) and Serological
Testing for the Years 2012, 2020 & 2027

ARGENTINA
Table 73: Argentina Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 74: Argentina Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 75: Argentina 15-Year Perspective for Zika Virus Testing
by Segment - Percentage Breakdown of Value Sales for Nucleic
Acid Amplification Testing (NAAT) and Serological Testing for
the Years 2012, 2020 & 2027

BRAZIL
Table 76: Brazil Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 77: Brazil Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 78: Brazil 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

MEXICO
Table 79: Mexico Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 80: Mexico Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 81: Mexico 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

REST OF LATIN AMERICA
Table 82: Rest of Latin America Current & Future Analysis for
Zika Virus Testing by Segment - Nucleic Acid Amplification
Testing (NAAT) and Serological Testing - Independent Analysis
of Annual Sales in US$ for the Years 2020 through 2027

Table 83: Rest of Latin America Historic Review for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019

Table 84: Rest of Latin America 15-Year Perspective for Zika
Virus Testing by Segment - Percentage Breakdown of Value Sales
for Nucleic Acid Amplification Testing (NAAT) and Serological
Testing for the Years 2012, 2020 & 2027

MIDDLE EAST
Table 85: Middle East Current & Future Analysis for Zika Virus
Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE
and Rest of Middle East Markets - Independent Analysis of
Annual Sales in US$ for Years 2020 through 2027

Table 86: Middle East Historic Review for Zika Virus Testing by
Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of
Middle East Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019

Table 87: Middle East 15-Year Perspective for Zika Virus
Testing by Geographic Region - Percentage Breakdown of Value
Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle
East Markets for Years 2012, 2020 & 2027

Table 88: Middle East Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 89: Middle East Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 90: Middle East 15-Year Perspective for Zika Virus
Testing by Segment - Percentage Breakdown of Value Sales for
Nucleic Acid Amplification Testing (NAAT) and Serological
Testing for the Years 2012, 2020 & 2027

IRAN
Table 91: Iran Current & Future Analysis for Zika Virus Testing
by Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027

Table 92: Iran Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 93: Iran 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

ISRAEL
Table 94: Israel Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 95: Israel Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 96: Israel 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

SAUDI ARABIA
Table 97: Saudi Arabia Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 98: Saudi Arabia Historic Review for Zika Virus Testing
by Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 99: Saudi Arabia 15-Year Perspective for Zika Virus
Testing by Segment - Percentage Breakdown of Value Sales for
Nucleic Acid Amplification Testing (NAAT) and Serological
Testing for the Years 2012, 2020 & 2027

UNITED ARAB EMIRATES
Table 100: UAE Current & Future Analysis for Zika Virus Testing
by Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027

Table 101: UAE Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 102: UAE 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

REST OF MIDDLE EAST
Table 103: Rest of Middle East Current & Future Analysis for
Zika Virus Testing by Segment - Nucleic Acid Amplification
Testing (NAAT) and Serological Testing - Independent Analysis
of Annual Sales in US$ for the Years 2020 through 2027

Table 104: Rest of Middle East Historic Review for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019

Table 105: Rest of Middle East 15-Year Perspective for Zika
Virus Testing by Segment - Percentage Breakdown of Value Sales
for Nucleic Acid Amplification Testing (NAAT) and Serological
Testing for the Years 2012, 2020 & 2027

AFRICA
Table 106: Africa Current & Future Analysis for Zika Virus
Testing by Segment - Nucleic Acid Amplification Testing (NAAT)
and Serological Testing - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027

Table 107: Africa Historic Review for Zika Virus Testing by
Segment - Nucleic Acid Amplification Testing (NAAT) and
Serological Testing Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019

Table 108: Africa 15-Year Perspective for Zika Virus Testing by
Segment - Percentage Breakdown of Value Sales for Nucleic Acid
Amplification Testing (NAAT) and Serological Testing for the
Years 2012, 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 47
Read the full report: https://www.reportlinker.com/p05960560/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001